StockNews.AI

Avalon GloboCare Regains Compliance with Nasdaq Stockholders' Equity Requirement, Launches Marketing for Automated Generative AI Video Platform

StockNews.AI • 11 hours

YOOV
High Materiality8/10

Information

FREEHOLD, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”)...

Original source

AI Summary

Avalon regained Nasdaq compliance, canceling a scheduled hearing. Compliance improves financial position and shareholder value outlook. Company plans to launch generative AI video platform. KetoAir™ breathalyzer device registered as Class I medical device. Proposed merger with YOOV Group is underway, with SEC filings ongoing.

Sentiment Rationale

Avalon's restoration of Nasdaq compliance enhances investor confidence. This can lead to higher stock prices, similar to historical cases where compliance issues resolved favorably.

Trading Thesis

The immediate lifting of regulatory pressures can result in short-term price upswing, although long-term effects rely on merger success and product launch performance.

Market-Moving

  • Avalon regained Nasdaq compliance, canceling a scheduled hearing.
  • Compliance improves financial position and shareholder value outlook.
  • Company plans to launch generative AI video platform.

Key Facts

  • Avalon regained Nasdaq compliance, canceling a scheduled hearing.
  • Compliance improves financial position and shareholder value outlook.
  • Company plans to launch generative AI video platform.
  • KetoAir™ breathalyzer device registered as Class I medical device.
  • Proposed merger with YOOV Group is underway, with SEC filings ongoing.

Companies Mentioned

  • YOOV (YOOV)

Corporate Developments

The article directly mentions compliance restoration and strategic expansion efforts, impacting investor sentiment and potential stock price.

Avalon GloboCare (NASDAQ: ALBT) Regains Compliance with Nasdaq Stockholders' Equity Requirement

FREEHOLD, N.J., January 12, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: ALBT), a company specializing in precision diagnostic consumer products and generative AI software, announced today that it has successfully regained compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b). This significant achievement signals a positive turn for the company, as it continues its commitment to enhancing shareholder value.

Compliance With Nasdaq Requirements

Following the notification from Nasdaq, Avalon is confirmed to be compliant with all applicable continued listing standards. Due to this compliance restoration, the previously scheduled hearing before the Nasdaq Hearings Panel has been canceled, ensuring that Avalon’s common stock will maintain its listing and trading status on the Nasdaq Capital Market.

CEO Meng Li Comments on Company Progress

“We are pleased to have regained compliance with Nasdaq’s minimum stockholders’ equity requirement, reflecting the progress we have made in strengthening our financial position and our continued focus on long-term shareholder value,” stated Meng Li, Avalon’s Interim Chief Executive Officer and Chief Operating Officer. “With full Nasdaq compliance restored, we believe we are well-positioned to execute on our growth initiatives, including launching marketing for our generative AI video platform and expanding across precision diagnostics and strategic assets.”

About Avalon GloboCare Corp.

Avalon GloboCare Corp. (NASDAQ: ALBT) focuses on developing innovative precision diagnostic consumer products and advancing intellectual property in cellular therapy and generative artificial intelligence. Through its subsidiary, Avalon Quantum AI, LLC, the company is currently marketing the KetoAir™ breathalyzer device, registered with the U.S. Food and Drug Administration as a Class I medical device, and plans to explore additional diagnostic applications in the future.

  • Company Symbol: ALBT
  • FDA-Registered Product: KetoAir™ breathalyzer
  • Focus Areas: Precision diagnostics, cellular therapy, AI software

Future Initiatives and Proposed Merger

As part of its growth strategy, Avalon is also navigating a proposed merger with YOOV Group Holding Limited. Relevant materials regarding this merger have been filed with the U.S. Securities and Exchange Commission (SEC), including a Registration Statement on Form S-4. Investors are encouraged to read the forthcoming proxy statement/prospectus and related documents, which will contain critical information regarding the proposed merger.

Readiness for Growth and Innovation

Avalon GloboCare's adherence to Nasdaq’s listing requirements demonstrates its commitment to maintaining a robust financial foundation. The company's focus on precision diagnostics and the development of generative AI technologies positions it well for future growth. As it continues to innovate and expand its offerings, stakeholders are advised to keep an eye on potential updates and developments.

For further information about Avalon GloboCare Corp., visit www.avalon-globocare.com. Please note that the information on the Company's website does not constitute a part of, nor is it incorporated by reference into, this press release.

Related News